Health · Medical Research · 3 hrs ago
Scientists propose targeting GPCRs to delay multiple diseases of aging
Researchers led by Stuart Maudsley of the Moffitt Cancer Center in Tampa propose rebalancing GPCRs to target several diseases of aging.
GPCRs are receptors on cell surfaces that pass signals into cells, and many existing medicines already target them.
The proposal focuses on heart disease, type 2 diabetes and Alzheimer’s, which are often treated as separate conditions.
The researchers argue that changes in GPCRs are linked to shared aging processes, including inflammation and weakening cell functions.
They propose adjusting different receptor signals rather than turning all GPCR activity up or down.
No drug or drug combination has been tested for slowing aging through this approach.
The authors say the idea is practical because many GPCRs can already be targeted with medicines, but it remains a plan to test, not a proven treatment.
Scientists propose rebalancing G protein-coupled receptors (GPCRs) to delay several diseases associated with aging.
The proposal treats GPCRs as an interconnected network rather than targeting each disease separately.
The authors say changes in GPCRs are linked to several processes associated with aging, including inflammation and failing mitochondria.
The proposal is based on a review of existing evidence, not a test of a drug or drug combination against aging.
About 40 percent of current drugs already act on GPCRs.
- Who
- Pharmacologists, including senior author Stuart Maudsley of the Moffitt Cancer Center.
- What
- They propose rebalancing GPCRs to delay several diseases of aging at once.
- When
- Published November 16, 2026.
- Where
- Not stated
- Why
- The authors say GPCRs connect to shared aging processes and are practical targets because many can already be targeted with medicines.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Publication date
- November 16, 2026
- Drug targets
- About 40 percent of current drugs act on GPCRs
- Human GPCRs
- Roughly 800 across five families
- Largest GPCR family
- About 720 receptors
- Senior author
- Stuart Maudsley, Moffitt Cancer Center, Tampa, Florida
What people are saying
Our argument is not that GPCRs have already been shown to outperform every other approach
It is that they offer an unusually practical set of entry points into this interconnected biology, because we already know how to target many of them with medicines
Crucially, this is not about switching all GPCR activity up or down